Neuronetics Reports Third Quarter 2022 Financial and Operating Results
Neuronetics, Inc. (NASDAQ: STIM) reported a 20% increase in Q3 2022 revenue, totaling $16.5 million, compared to $13.8 million in Q3 2021. The U.S. treatment session revenue reached a record $11.9 million, with a 51% rise in NeuroStar System revenue. The company raised its full-year revenue guidance to $63-64 million. Positive regulatory updates include FDA clearance for the D-Tect™ MT Accessory, and multiple TMS coverage policies improving patient access. However, operating expenses increased by 14.6% to $20.4 million, with a net loss of $(7.6) million, slightly better than the previous year.
- 20% increase in total revenue year-over-year, reaching $16.5 million.
- Record U.S. treatment session revenue of $11.9 million.
- 51% increase in NeuroStar System revenue compared to Q3 2021.
- Raised full-year revenue guidance to $63-64 million.
- FDA 510(k) clearance received for D-Tect™ MT Accessory.
- Positive TMS coverage policies expected to enhance patient access for 8 million lives.
- Operating expenses rose by 14.6% to $20.4 million.
- Net loss of $(7.6) million, although slightly improved from last year's $(8.2) million.
MALVERN, Pa., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, today announced its financial and operating results for the third quarter of 2022.
Third Quarter 2022 Highlights
- Third quarter 2022 revenue of
$16.5 million , represents a20% increase as compared to the third quarter 2021 - Achieved record quarterly U.S. treatment session revenue of
$11.9 million in the third quarter 2022, compared to$10.3 million in third quarter 2021 - Reached an all time U.S. treatment session utilization record in the third quarter
- Increased NeuroStar System revenue
51% over the third quarter of 2021 - Raising revenue guidance for full year 2022 to be between
$63.0 million and$64.0 million
Recent Operational Highlights
- Received FDA 510(k) clearance for D-Tect™ MT Accessory
- Positive TMS coverage policies published or proposed which expand patient access to NeuroStar Advanced Therapy system for both MDD and OCD
Recent Marketing Highlights
- Grand opening of NeuroStar University (NSU) in Charlotte, North Carolina
- Tap Into a New Possibility for Depression campaign drove over 30 million impressions, up
150% compared to campaigns run during third quarter of 2021 - Achieved milestones of over 141,070 global patients treated with more than 5.0 million of our Treatment Sessions, a Company record
“Our strong performance in the third quarter reflects the positive impacts of our ongoing strategic initiatives such as the revamped sales force, innovative marketing programs, and continued physician and patient education. Performance was highlighted by record US Treatment Sessions revenue and utilization, while also achieving
Third Quarter 2022 Financial and Operating Results for the Three Months Ended September 30, 2022
| Revenues by Geography | ||||||||||
| Three Months Ended September 30, | ||||||||||
| 2022 | 2021 | |||||||||
| Amount | Amount | % Change | ||||||||
| (in thousands, except percentages) | ||||||||||
| United States | $ | 16,244 | $ | 13,280 | 22 | % | ||||
| International | 254 | 519 | (51) | % | ||||||
| Total revenues | $ | 16,498 | $ | 13,799 | 20 | % | ||||
Total revenue for the three months ended September 30, 2022 was
| U.S. Revenues by Product Category | |||||||||
| Three Months Ended September 30, | |||||||||
| 2022 | 2021 | ||||||||
| Amount | Amount | % Change | |||||||
| (in thousands, except percentages) | |||||||||
| NeuroStar Advanced Therapy System | $ | 3,934 | $ | 2,612 | 51 | % | |||
| Treatment sessions | 11,864 | $ | 10,259 | 16 | % | ||||
| Other | 446 | $ | 409 | 9 | % | ||||
| Total U.S. revenues | $ | 16,244 | $ | 13,280 | 22 | % | |||
U.S. NeuroStar Advanced Therapy System revenue for the three months ended September 30, 2022 was
U.S. Treatment Session revenue for the three months ended September 30, 2022 was
In the third quarter of 2022, U.S. treatment session revenue per active site increased to
Gross margin for the third quarter of 2022 was
Operating expenses during the third quarter of 2022 were
Net loss for the third quarter of 2022 was
EBITDA for the third quarter of 2022 was
Cash and cash equivalents were
TMS Coverage Policies Updates
In October of 2022, multiple Medicare Administrative Contractors (MACs) published and proposed Medicare coverage policies to reduce the number of medication trials required for TMS eligibility, leading to increased access to NeuroStar as a non-drug alternative for treatment resistant mental disorders. The published and proposed updates will affect nearly 8 million covered lives. CGS MAC has published an updated TMS coverage policy, effective December 4, 2022, that reduces the number of prior medication failures for TMS eligibility from four down to two for people suffering from major depressive disorder (MDD). NGS MAC has published a proposed Local Coverage Decision (LCD) considering TMS coverage for obsessive-compulsive disorder (OCD) and is also considering an MDD policy criteria change that would reduce the number of prior medication failures for TMS eligibility from four down to two.
510(k) Clearance for D-Tect MT Accessory
The Company has received 510(k) clearance for it’s D-Tect™ MT Accessory, which is the latest innovation in NeuroStar’s commitment to simplify the motor threshold determination for physicians. The FDA-cleared technology aids clinicians by visually reporting the magnitude of finger movements during motor threshold (MT) mapping for treatment of major depressive disorder (MDD). D-Tect also allows the MT determination to be performed by only one person. In addition, practices will be trained on this new product at NeuroStar University, which recently opened in Charlotte, North Carolina.
Grand Opening of NeuroStar University (NSU)
In September, the Company hosted a ribbon-cutting ceremony to celebrate the grand opening of NeuroStar University in Charlotte, NC. Local government officials, NeuroStar patients and providers, and leaders in the mental health industry were among the 75 attendees. NSU will teach new and existing customers how to enhance patient outcomes, connect with other specialists in their field, and grow their practices using clinical education, enhanced patient awareness and consultation techniques.
Business Outlook
For the full year 2022, the Company now expects total worldwide revenue to be between
For the full year 2022, the Company continues to expect total operating expenses to be between
For the fourth quarter of 2022, the Company expects to report total worldwide revenue of between
Webcast and Conference Call Information
Neuronetics’ management team will host a conference call on November 8, 2022, beginning at 8:30 a.m. Eastern Time.
The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/h3amkwib. To listen to the conference call on your telephone, participants may register for the call here. While it is not required, it is recommended you join 10 minutes prior to the event start. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Neuronetics’ website at ir.neuronetics.com.
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience and the largest transcranial magnetic stimulation (“TMS”) company in the industry, Neuronetics is redefining patient and physician expectations by designing and developing products that improve the quality of life for people suffering from neurohealth conditions. An FDA-cleared, non-drug, noninvasive treatment for people with depression, Neuronetics’ NeuroStar® Advanced Therapy system is the leading TMS treatment for major depressive disorder (“MDD”) in adults with over 4.8 million treatments delivered. NeuroStar is widely researched and backed by the largest clinical data set of any TMS system for depression, including the world’s largest depression Outcomes Registry. Our NeuroStar® Advanced Therapy system is also FDA-cleared to treat people suffering from obsessive-compulsive disorder, as well as for the treatment of comorbid anxiety symptoms (“anxious depression”) for adults with MDD suffering from anxiety symptoms. Neuronetics is committed to transforming lives by offering an exceptional treatment option that aims to produce extraordinary results. For safety information and indications for use, visit NeuroStar.com.
“Safe harbor” statement under the Private Securities Litigation Reform Act of 1995:
Statements in the press release regarding Neuronetics, Inc. (the “Company”) that are not historical facts constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as “outlook,” “potential,” “believe,” “expect,” “plan,” “anticipate,” “predict,” “may,” “will,” “could,” “would” and “should” as well as the negative of these terms and similar expressions. These statements include those relating to the Company’s business outlook and current expectations for upcoming quarter and fiscal year 2022, including with respect to revenue, operating expense, growth, and any statements of assumptions underlying any of the foregoing items. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, risks and uncertainties related to: the impact of COVID 19 on the Company’s operational and budget plans as well as general political and economic conditions, including as a result of efforts by governmental authorities to mitigate COVID 19, such as travel restrictions and third-party business closures and the related impact on resource allocations, manufacturing and supply chains and patient access to commercial products; the Company’s ability to execute its business continuity; the Company’s ability to achieve or sustain profitable operations due to its history of losses; the Company’s reliance on the sale and usage of its NeuroStar Advanced Therapy for Mental Health System to generate revenues; the scale and efficacy of the Company’s salesforce as well as the Company’s ability to retain talent; availability of coverage and reimbursement from third-party payors for treatments using the Company’s products; physician and patient demand for treatments using the Company’s products; developments in respect of competing technologies and therapies for the indications that the Company’s products treat; product defects; the Company’s ability to obtain and maintain intellectual property protection for its technology; developments in clinical trials or regulatory review of NeuroStar Advanced Therapy for Mental Health System for additional indications; and developments in regulation in the United States and other applicable jurisdictions. For a discussion of these and other related risks, please refer to the Company’s recent SEC filings which are available on the SEC’s website at www.sec.gov. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, or changes in the Company’s expectations.
Investor Contact:
Mike Vallie or Mark Klausner
Westwicke Partners
443-213-0499
ir@neuronetics.com
Media Contact:
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com
NEURONETICS, INC.
Statements of Operations
(In thousands, except per share data)
| Three Months ended | Nine months ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Revenues | $ | 16,498 | $ | 13,799 | $ | 47,008 | $ | 40,290 | ||||||||
| Cost of revenues | 3,570 | 3,144 | 11,093 | 8,115 | ||||||||||||
| Gross Profit | 12,928 | 10,655 | 35,915 | 32,175 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Sales and marketing | 11,643 | 9,827 | 37,977 | 27,431 | ||||||||||||
| General and administrative | 6,391 | 6,435 | 19,125 | 19,220 | ||||||||||||
| Research and development | 2,348 | 1,575 | 6,197 | 6,179 | ||||||||||||
| Total operating expenses | 20,382 | 17,837 | 63,299 | 52,830 | ||||||||||||
| Loss from Operations | (7,454 | ) | (7,182 | ) | (27,384 | ) | (20,655 | ) | ||||||||
| Other (income) expense: | ||||||||||||||||
| Interest expense | 1,061 | 993 | 3,039 | 2,955 | ||||||||||||
| Other income, net | (906 | ) | (24 | ) | (1,554 | ) | (53 | ) | ||||||||
| Net Loss | $ | (7,609 | ) | $ | (8,151 | ) | $ | (28,869 | ) | $ | (23,557 | ) | ||||
| Net loss per share of common stock outstanding, basic and diluted | $ | (0.28 | ) | $ | (0.31 | ) | $ | (1.08 | ) | $ | (0.94 | ) | ||||
| Weighted-average common shares outstanding, basic and diluted | 26,965 | 26,301 | 26,797 | 25,179 | ||||||||||||
NEURONETICS, INC.
Balance Sheets
(In thousands, except per share data)
| September 30, | December 31, | |||||||
| 2022 | 2021 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 73,698 | $ | 94,141 | ||||
| Accounts receivable, net | 11,963 | 7,706 | ||||||
| Inventory | 8,573 | 6,563 | ||||||
| Current portion of net investments in sales-type leases | 1,874 | 2,198 | ||||||
| Current portion of prepaid commission expense | 1,871 | 1,559 | ||||||
| Current portion of note receivables | 80 | 74 | ||||||
| Prepaid expenses and other current assets | 3,037 | 3,090 | ||||||
| Total current assets | 101,096 | 115,331 | ||||||
| Property and equipment, net | 2,109 | 1,220 | ||||||
| Operating lease right-of-use assets | 3,459 | 3,884 | ||||||
| Net investments in sales-type leases | 1,617 | 1,697 | ||||||
| Prepaid commission expense | 7,305 | 6,763 | ||||||
| Long-term note receivable | 94 | 10,110 | ||||||
| Other assets | 3,555 | 2,218 | ||||||
| Total Assets | $ | 119,235 | $ | 141,223 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 2,350 | $ | 4,299 | ||||
| Accrued expenses | 11,493 | 8,233 | ||||||
| Deferred revenue | 1,732 | 2,501 | ||||||
| Current portion of operating lease liabilities | 818 | 670 | ||||||
| Current portion of long-term debt, net | 8,750 | — | ||||||
| Total current liabilities | 25,143 | 15,703 | ||||||
| Long-term debt, net | 27,009 | 35,335 | ||||||
| Deferred revenue | 981 | 1,471 | ||||||
| Operating lease liabilities | 3,111 | 3,539 | ||||||
| Total Liabilities | 56,244 | 56,048 | ||||||
| Commitments and contingencies (Note 17) | — | — | ||||||
| Stockholders’ Equity: | ||||||||
| Preferred stock, | ||||||||
| outstanding on September 30, 2022, and December 31, 2021 | — | — | ||||||
| Common stock, | ||||||||
| shares issued and outstanding on September 30, 2022, and December 31, 2021, respectively | 270 | 264 | ||||||
| Additional paid-in capital | 400,323 | 393,644 | ||||||
| Accumulated deficit | (337,602 | ) | (308,733 | ) | ||||
| Total Stockholders’ Equity | 62,991 | 85,175 | ||||||
| Total Liabilities and Stockholders’ Equity | $ | 119,235 | $ | 141,223 | ||||
NEURONETICS, INC.
Statements of Cash Flows
(In thousands)
| Nine months ended September 30, | ||||||||
| 2022 | 2021 | |||||||
| Cash Flows from Operating Activities: | ||||||||
| Net loss | $ | (28,869 | ) | $ | (23,557 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization | 1,044 | 768 | ||||||
| Share-based compensation | 6,633 | 6,166 | ||||||
| Non-cash interest expense | 513 | 484 | ||||||
| Cost of rental units purchased by customers | 92 | 137 | ||||||
| Changes in certain assets and liabilities: | ||||||||
| Accounts receivable, net | (4,257 | ) | (3,097 | ) | ||||
| Inventory | (2,299 | ) | (1,870 | ) | ||||
| Net investment in sales-type leases | 381 | 341 | ||||||
| Prepaid commission expense | (854 | ) | (602 | ) | ||||
| Prepaid expenses and other assets | 176 | (453 | ) | |||||
| Accounts payable | (2,199 | ) | (840 | ) | ||||
| Accrued expenses | 3,260 | (405 | ) | |||||
| Deferred revenue | (1,260 | ) | (531 | ) | ||||
| Net Cash Used in Operating Activities | (27,639 | ) | (23,459 | ) | ||||
| Cash Flows from Investing Activities: | ||||||||
| Purchases of property and equipment and capitalized software | (2,766 | ) | (1,552 | ) | ||||
| Repayment (Issuance) of promissory note | 10,000 | (7,486 | ) | |||||
| Net Cash provided by (Used in) Investing Activities | 7,234 | (9,038 | ) | |||||
| Cash Flows from Financing Activities: | ||||||||
| Payments of debt issuance costs | (90 | ) | — | |||||
| Proceeds from exercises of stock options | 52 | 2,403 | ||||||
| Proceeds from common stock offering | — | 80,972 | ||||||
| Payments of common stock offering issuance costs | — | (401 | ) | |||||
| Net Cash (Used) Provided by Financing Activities | (38 | ) | 82,974 | |||||
| Net (Decrease) Increase in Cash and Cash Equivalents | (20,443 | ) | 50,477 | |||||
| Cash and Cash Equivalents, Beginning of Period | 94,141 | 48,957 | ||||||
| Cash and Cash Equivalents, End of Period | $ | 73,698 | $ | 99,434 | ||||
Non-GAAP Financial Measures (Unaudited)
EBITDA is not a measure of financial performance under generally accepted accounting principles in the United States, or GAAP, and should not be construed as a substitute for, or superior to, GAAP net loss. However, management uses both the GAAP and non-GAAP financial measures internally to evaluate and manage the Company’s operations and to better understand its business. Further, management believes the addition of the non-GAAP financial measure provides meaningful supplementary information to, and facilitates analysis by, investors in evaluating the Company’s financial performance, results of operations and trends. The Company’s calculation of EBITDA may not be comparable to similarly designated measures reported by other companies, because companies and investors may differ as to what type of events warrant adjustment.
The following table reconciles reported net loss to EBITDA:
| Three Months ended | Nine months ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| (in thousands) | (in thousands) | |||||||||||||||
| Net loss | $ | (7,609 | ) | $ | (8,151 | ) | $ | (28,869 | ) | $ | (23,557 | ) | ||||
| Interest expense | 1,061 | 993 | 3,039 | 2,955 | ||||||||||||
| Income taxes | — | — | — | — | ||||||||||||
| Depreciation and amortization | 387 | 216 | 1,044 | 768 | ||||||||||||
| EBITDA | $ | (6,161 | ) | $ | (6,942 | ) | $ | (24,786 | ) | $ | (19,834 | ) | ||||
FAQ
What were Neuronetics' Q3 2022 revenue figures?
How did NeuroStar System revenue perform in the third quarter of 2022?
What is the updated revenue guidance for Neuronetics for 2022?
What are the operating expenses reported for Q3 2022?
What recent regulatory approval did Neuronetics receive?
How does the new TMS coverage policy affect patient access?
